Top Ten most popular articles on Pharmafile.com this week
pharmafile | June 5, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | COVID-19, coronavirus
This week has seen the development of coronavirus vaccines move forward, as the Trump administration has selected the finalists for the COVID-19 vaccine it is seeking to make widely available by the end of the year, while the US has given $1 billion to AstraZeneca to advance the development and production of the vaccine they are creating in collaboration with the Oxford University.
In terms of COVID-19 treatments, Kings College London has launched a clinical trial to investigate how effective a formulation of ibuoprofen is in reducing respiratory failure in coronavirus patients, while Russia will start its roll out of the anti-viral drug Avifavir to COVID-19 patients next week.
Kings College London has launched a clinical trial to investigate how effective a formulation of ibuoprofen is in reducing respiratory failure in coronavirus patients.
2. FDA advises recall of diabetes drug metformin over carcinogen concerns
The FDA has asked that multiple pharmaceutical companies recall the formulations of their diabetes drug metformin after the regulatory body found high levels of a possible carcinogen.
3. US donates $1 billion to Oxford University’s COVID-19 vaccine in exchange for 300 million doses
The US has given $1 billion to AstraZeneca to advance the development and production of the vaccine they are creating in collaboration with the Oxford University.
4. Lancet expresses concern over published hydroxychloroquine and chloroquine paper
The Lancet’s editors have expressed their concerns over a paper published in their journal that said hydroxychloroquine and chloroquine was dangerous for use in COVID-19 patients.
5. Trump’s Operation Warp Speed selects Pfizer, Merck, AstraZeneca and Moderna as vaccine finalists
The Trump administration has selected the finalists for the COVID-19 vaccine it is seeking to make widely available by the end of the year.
6. Russia to begin administering anti-viral COVID-19 drug next week
Russia will start its roll out of the anti-viral drug Avifavir (favipiravir) to COVID-19 patients next week, according to the Russian Direct Investment Fund (RDIF).
7. First ever benefit-risk analysis is “favourable” for remdesivir as COVID-19 treatment
The UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s remdesivir, one of the leading hope in the treatment of COVID-19, noting that it found the drug to have a tentatively “favourable” profile.
The Association of American Physicians & Surgeons have filed a lawsuit against the FDA due to it blocking widespread access to hydroxychloroquine, previously touted by President Trump as an effective COVID-19 treatment.
9. Hydroxychloroquine does not work as a preventative against COVID-19, new study finds
The malaria drug hydroxychloroquine does not protect people from COVID-19, according to a new study led by researchers at the University of Minnesota.
10. Antidepressant Zoloft falls into shortage due to anxiety around COVID-19
The FDA has listed the antidepressant Zoloft to its catalogue of drugs that are in short supply in the United States from a heightened demand due to the coronavirus.
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
